While monotherapy with PD-1/PD-L1 inhibitors has demonstrated clinical benefits in HCC, particularly in the second-line setting, its efficacy remains constrained by low ORR and short PFS. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.